| アブストラクト | OBJECTIVES: The objective of the study was to describe treatment patterns in patients newly diagnosed with Parkinson's disease (PD) in the United States (US) and the United Kingdom (UK). METHODS: This retrospective cohort study used the US IBM MarketScan database (2012-2017) and the UK Clinical Practice Research Datalink (CPRD) (2004-2015) database to describe treatment patterns in incident PD cases. Patients fulfilling the case definition of PD, >/=30 years, with a 2-year baseline period prior to the index date (date of PD diagnosis), and >/=90 days of follow-up were included in the study. Treatment was classified as monotherapy (one PD medication for >/=60 continuous days), polytherapy (at least two PD medications concurrently for >/=60 days), or untreated (no PD medication prescription). Treatment patterns described included type of medication, duration and outcome of treatment. RESULTS: There were 11,280 patients in IBM MarketScan and 7775 patients in CPRD who fulfilled the study criteria. The proportion of treated patients was 62.4% (US) and 78.6% (UK). The majority of patients were prescribed monotherapy as first-line treatment (US: 85.2%, UK: 68.5%). Levodopa was the most frequently prescribed first-line medication (US: 70.1%, UK: 29.0%). There were 57.9% in the US and 23.8% in the UK who remained on the first monotherapy treatment till the end of the study. CONCLUSION: The study has highlighted the current treatment practices in the US and UK, and underscored differences in the two regions impacted by treatment policies and guidelines. |
|---|
| 投稿日 | 2019/11/23 |
|---|
| 投稿者 | Kalilani, Linda; Friesen, David; Boudiaf, Nada; Asgharnejad, Mahnaz |
|---|
| ジャーナル名 | PloS one |
|---|
| 組織名 | UCB Pharma, Raleigh, North Carolina, United States of America.;UCB Pharma, Slough, United Kingdom. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/31756215/ |
|---|
